Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

212
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
212
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

849
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
849
Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

397
Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
397
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

236
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
236
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

821
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
821

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The cardiodiabetologist: not just a question of blood glucose levels.

European heart journal supplements : journal of the European Society of Cardiology·2025
Same author

The new in anticoagulation: factor XI inhibitors.

European heart journal supplements : journal of the European Society of Cardiology·2023
Same author

Pollution and coronary risk: how much does it matter?

European heart journal supplements : journal of the European Society of Cardiology·2022
Same author

New insights from the MESA study: increased high-sensitivity troponins as a cardiovascular risk factor.

European heart journal supplements : journal of the European Society of Cardiology·2021
Same author

Challenges in ischaemic heart disease: not sleeping enough, not brushing your teeth, and skipping breakfast-three ways of increasing your risk of myocardial infarction?

European heart journal supplements : journal of the European Society of Cardiology·2021
Same author

A case report of multisite arterial thrombosis in a patient with coronavirus disease 2019 (COVID-19).

European heart journal. Case reports·2021

Related Experiment Video

Updated: Mar 19, 2026

Manipulation of Ploidy in Caenorhabditis elegans
07:54

Manipulation of Ploidy in Caenorhabditis elegans

Published on: March 15, 2018

11.6K

Polypill: quo vadis?

Francesca Muscente1, Raffaele De Caterina

  • 1aInstitute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University - Chieti-Pescara, Chieti bG. Monasterio Foundation, Pisa, Italy.

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|June 25, 2016
PubMed
Summary

Cardiovascular disease (CVD) prevention strategies can be improved with polypills, which combine multiple medications. These pills may enhance treatment adherence and accessibility, particularly in low-income countries, though long-term effects require further study.

More Related Videos

Inducing Polyp Bail-out in Coral Colonies to Obtain Individualized Micropropagates for Laboratory Experimental Use
07:23

Inducing Polyp Bail-out in Coral Colonies to Obtain Individualized Micropropagates for Laboratory Experimental Use

Published on: April 28, 2022

3.7K
Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

16.5K

Related Experiment Videos

Last Updated: Mar 19, 2026

Manipulation of Ploidy in Caenorhabditis elegans
07:54

Manipulation of Ploidy in Caenorhabditis elegans

Published on: March 15, 2018

11.6K
Inducing Polyp Bail-out in Coral Colonies to Obtain Individualized Micropropagates for Laboratory Experimental Use
07:23

Inducing Polyp Bail-out in Coral Colonies to Obtain Individualized Micropropagates for Laboratory Experimental Use

Published on: April 28, 2022

3.7K
Reproductive Techniques for Ovarian Monitoring and Control in Amphibians
04:37

Reproductive Techniques for Ovarian Monitoring and Control in Amphibians

Published on: May 12, 2019

16.5K

Area of Science:

  • Cardiology
  • Public Health
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) remains the leading global cause of mortality.
  • Increasing CVD incidence in low- and middle-income countries is linked to health policy, medication access, and patient adherence issues.
  • Polypills (fixed-dose combination pills) offer a potential strategy to improve CVD prevention by combining multiple drugs.

Purpose of the Study:

  • To evaluate the potential of polypills in enhancing cardiovascular disease prevention strategies.
  • To assess the benefits and limitations of polypills regarding cost, accessibility, and patient adherence.
  • To explore optimal patient selection for polypill therapy.

Main Methods:

  • Review of clinical trials on fixed-dose combination pills for CVD risk factors.
  • Analysis of projected improvements in cardiovascular endpoints based on risk factor reduction.
  • Discussion of challenges including long-term adherence, cost-effectiveness, and population-wide application.

Main Results:

  • Clinical trials indicate polypills are well-tolerated and effectively reduce cardiovascular risk factors like blood pressure and LDL cholesterol.
  • Projected improvements in major cardiovascular endpoints range from 60-70% with polypill use.
  • Uncertainty persists regarding hard endpoints, long-term adherence, cost-effectiveness, and the 'medicalization' of asymptomatic individuals.

Conclusions:

  • Polypills show promise for improving CVD prevention, especially in resource-limited settings, by potentially increasing adherence and accessibility.
  • Targeting specific high-risk populations, possibly identified through combined risk scores (e.g., Coronary Artery Calcium Score and Framingham Risk Score), may be more practical than treating all individuals over 50.
  • Further research and ongoing trials are necessary to resolve current debates on polypill efficacy, cost-effectiveness, and long-term outcomes.